Population-based study of risk of breast cancer in carriers of BRCA2 mutation

被引:271
作者
Thorlacius, S
Struewing, JP
Hartge, P
Olafsdottir, GH
Sigvaldason, H
Tryggvadottir, L
Wacholder, S
Tulinius, H
Eyfjörd, JE
机构
[1] Iceland Canc Soc, Mol & Cell Biol Res Lab, Reykjavik, Iceland
[2] Iceland Canc Soc, Iceland Canc Registry, Reykjavik, Iceland
[3] NCI, Div Canc Epidemiol & Genet, NIH, Bethesda, MD 20892 USA
关键词
D O I
10.1016/S0140-6736(98)03300-5
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background Estimates of an 80-90% risk of breast cancer for carriers of germline mutations in the BRCA1 and BRCA2 genes are based on studies of families at high risk of breast cancer. Risk estimates for a population are possible if the mutation status of a representative sample of that population can be assessed. In Iceland, one common founder BRCA2 mutation occurs in 0.6% of the population. Iceland has a population-based cancer registry and a large collection of pedigrees, and estimation of cancer risk in mutation carriers is therefore possible. Methods We studied 575 breast-cancer patients, 541 women and 34 men unselected for family history of breast cancer. Data on cancer in first-degree relatives were available from the cancer registry. Risk of cancer was estimated by comparing the history of cancer in first-degree relatives of carriers and non-carriers. Findings 56 (10.4%) of the 541 women and 13 (38%) of the 34 men carried the 999del5 mutation. The estimated risk of breast cancer at age 50 for all female carriers of the 999de15 mutation was 17.0% (95% CI 9.1-25.9) and 37.2%(22.4-53.9) at age 70. Interpretation The results of our population-based study show that the mean risk of breast cancer in carriers of mutation in BRCA2 is lower than previously suggested. Individual risk assessment will, however, have to take account of family history.
引用
收藏
页码:1337 / 1339
页数:3
相关论文
共 26 条
[1]  
Bergthorsson JT, 1998, HUM MUTAT, pS195
[2]  
BJARNASON O, 1966, CANCER INCIDENCE 5 C, P168
[3]   Mutations and polymorphisms in the familial early-onset breast cancer (BRCA1) gene [J].
Couch, FJ ;
Weber, BL ;
Borresen, AL ;
Brody, L ;
Casey, G ;
Devilee, P ;
Fitzgerald, M ;
Friend, S ;
Gayther, S ;
Goldgar, D ;
Murphy, P ;
Szabo, C ;
Weber, B ;
Wiseman, R ;
Anderson, T ;
Durocher, F ;
Ganguly, A ;
King, MC ;
Lenoir, G ;
Narod, S ;
Olopade, O ;
Plummer, S ;
Ponder, B ;
Serova, O ;
Simard, J ;
Stratton, M ;
Warren, B .
HUMAN MUTATION, 1996, 8 (01) :8-18
[4]  
EASTON DF, 1995, AM J HUM GENET, V56, P265
[5]   Frequency and carrier risk associated with common BRCA1 and BRCA2 mutations in Ashkenazi Jewish breast cancer patients [J].
Fodor, FH ;
Weston, A ;
Bleiweiss, IJ ;
McCurdy, LD ;
Walsh, MM ;
Tartter, PI ;
Brower, ST ;
Eng, CM .
AMERICAN JOURNAL OF HUMAN GENETICS, 1998, 63 (01) :45-51
[6]   Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families [J].
Ford, D ;
Easton, DF ;
Stratton, M ;
Narod, S ;
Goldgar, D ;
Devilee, P ;
Bishop, DT ;
Weber, B ;
Lenoir, G ;
Chang-Claude, J ;
Sobol, H ;
Teare, MD ;
Struewing, J ;
Arason, A ;
Scherneck, S ;
Peto, J ;
Rebbeck, TR ;
Tonin, P ;
Neuhausen, S ;
Barkardottir, R ;
Eyfjord, J ;
Lynch, H ;
Ponder, BAJ ;
Gayther, SA ;
Birch, JM ;
Lindblom, A ;
Stoppa-Lyonnet, D ;
Bignon, Y ;
Borg, A ;
Hamann, U ;
Haites, N ;
Scott, RJ ;
Maugard, CM ;
Vasen, H .
AMERICAN JOURNAL OF HUMAN GENETICS, 1998, 62 (03) :676-689
[7]   Variation of risks of breast and ovarian cancer associated with different germline mutations of the BRCA2 gene [J].
Gayther, SA ;
Mangion, J ;
Russell, P ;
Seal, S ;
Barfoot, R ;
Ponder, BAJ ;
Stratton, MR ;
Easton, D .
NATURE GENETICS, 1997, 15 (01) :103-105
[8]   GERMLINE MUTATIONS OF THE BRCA1 GENE IN BREAST AND OVARIAN-CANCER FAMILIES PROVIDE EVIDENCE FOR A GENOTYPE-PHENOTYPE CORRELATION [J].
GAYTHER, SA ;
WARREN, W ;
MAZOYER, S ;
RUSSELL, PA ;
HARRINGTON, PA ;
CHIANO, M ;
SEAL, S ;
HAMOUDI, R ;
VANRENSBURG, EJ ;
DUNNING, AM ;
LOVE, R ;
EVANS, G ;
EASTON, D ;
CLAYTON, D ;
STRATTON, MR ;
PONDER, BAJ .
NATURE GENETICS, 1995, 11 (04) :428-433
[9]   Growth retardation and tumour inhibition by BRCA1 [J].
Holt, JT ;
Thompson, ME ;
Szabo, C ;
RobinsonBenion, C ;
Arteaga, CL ;
King, MC ;
Jensen, RA .
NATURE GENETICS, 1996, 12 (03) :298-302
[10]  
*IARC, 1997, IARC SCI PUBL, V143, P514